ArticleClinical & experimental metastasis2020
Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients.
Article in Clinical & experimental metastasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.The oncologist · 2024Trial
- Machine Learning-Based Prediction of Brain Metastasis at Initial Diagnosis in Small-Cell Lung Cancer: Model Development and SHAP Interpretation Study.Cancer reports (Hoboken, N.J.) · 2026Article
- Construction of a nomogram to guide prophylactic cranial irradiation in extensive‑stage small cell lung cancer.Oncology letters · 2025Article
- Comparative survival outcome of synchronous and metachronous brain metastasis from colorectal cancer: A meta‑analysis.Oncology letters · 2025Article
- Construction, validation, and visualization of a web-based nomogram to predict overall survival in small-cell lung cancer patients with brain metastasis.Cancer causes & control : CCC · 2024Article
- Prognostic factors in extensive-stage small cell lung cancer patients with organ-specific metastasis: unveiling commonalities and disparities.Journal of cancer research and clinical oncology · 2024Article
- Development and validation of a nomogram for the prediction of brain metastases in small cell lung cancer.The clinical respiratory journal · 2023Article
- Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: A population-based study.Cancer medicine · 2023Article
- Prediction of distant organ metastasis and overall survival of lung cancer patients: a SEER population-based cohort study.Frontiers in oncology · 2023Article
- Predictive value of clinical characteristics on risk and prognosis of synchronous brain metastases in small-cell lung cancer patients: A population-based study.Cancer medicine · 2023Article
- A novel nomogram predicting cancer-specific survival in small cell lung cancer patients with brain metastasis.Translational cancer research · 2022Article
- Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.Journal of neurology · 2022Article
- Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.Clinical Medicine Insights. Oncology · 2022Article
- Machine Learning for the Prediction of Synchronous Organ-Specific Metastasis in Patients With Lung Cancer.Frontiers in oncology · 2022Article
- Prophylactic cranial irradiation in patients with small cell lung cancer in The Netherlands: A population-based study.Clinical and translational radiation oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with small cell lung cancer (SCLC) are more likely to have synchronous brain metastasis (SBM) at the time of diagnosis than patients with any other extracranial primary malignancy. We sought to identify which factors predicted an increased risk of SBM in SCLC as well as which factors affected the prognosis of these patients. 38,956 Patients in the Surveillance, Epidemiology, and End Results (SEER) database with microscopically confirmed SCLC from 2010 to 2016 were identified. 6264 (16.1%) Patients with SCLC had SBM at the time of diagnosis. In the multivariable logistic regression, disease specific factors that were predictive of SBM were primary tumor size > 7 cm (adjusted OR = 1.14, 95% CI [1.02, 1.28], p = 0.02), synchronous lung metastases, and synchronous bone metastases. Demographic specific factors predictive of increased SBM risk in this model were younger age, male sex, and race (American Indian/Alaska Native and black patients). Patients insured through Medicaid were less likely to present with SBM. In the multivariate Cox proportional hazards model, lack of insurance was the strongest predictor of mortality (adjusted HR = 1.47, 95% CI [1.26, 1.73], p < 0.001). Other factors associated with an increased risk of mortality include male sex, older age, health insurance coverage through Medicaid, synchronous liver metastasis, synchronous lung metastasis, and primary tumor size > 7 cm. In contrast, Asian patients had a lower risk of mortality. This study identifies risk factors for SBM among patients with SCLC, as well as indicators of prognosis among this patient population.
Indexed as
Identifiers
32500410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.